Company intelligence / Profile preview

Accera, Inc.

Broomfield, Colorado, USAacera.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Accera, Inc. develops novel small molecule therapeutics targeting metabolic dysfunction in neurodegenerative diseases, with a primary focus on Alzheimer’s disease. Its lead candidate AC‑1204 completed enrollment for a U.S.-based Phase 3 trial by May 2016 and planned to report topline results later that year. The company previously marketed Axona as a medical food but pivoted to drug development after regulatory criticism. No recent clinical results are available post‑2016.[5][6]

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

tricaprilin

Phase 3

Indications: Alzheimer's disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Accera, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accera, Inc..

Explore the full profile